Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 - Wikidata - wikimedia - TriplyDB

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2

http://www.wikidata.org/entity/Q35051651

about

Dynamin2 downregulation delays EGFR endocytic trafficking and promotes EGFR signaling and invasion in hepatocellular carcinoma.Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity.

P2860

Q35402681-C6D781C4-C91B-4C9F-A5B3-C9E7D1329368 Q47871695-39D2A736-231B-46BF-A14B-30D86692201C

P2860

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2

http://www.wikidata.org/entity/Q35051651

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Preclinical antitumor activity ...... ermal growth factor receptor 2

@ast

Preclinical antitumor activity ...... ermal growth factor receptor 2

@en

type

label

Preclinical antitumor activity ...... ermal growth factor receptor 2

@ast

Preclinical antitumor activity ...... ermal growth factor receptor 2

@en

prefLabel

Preclinical antitumor activity ...... ermal growth factor receptor 2

@ast

Preclinical antitumor activity ...... ermal growth factor receptor 2

@en

P1433

Q35051651-4953F637-B8E3-411C-A9FA-3A590E41C1AE

P1476

Q35051651-E4713A69-0A5D-4441-AE41-DB19FB6CEA72

P2093

Q35051651-11282D79-1069-49B9-AA57-A2ED443E8948

Q35051651-12C4B4B6-5E8C-4CBC-88D5-165F5F89DE9E

Q35051651-33FC9922-A8FD-4186-A3B3-A933D927BB80

Q35051651-41DB9D44-57F0-44BD-9622-35E05305C12D

Q35051651-54D43189-902E-43F2-B732-EA1C8BACD768

Q35051651-57A8F6B3-E092-410A-B5B2-AEB1628092DA

Q35051651-5BE5677C-D5E2-4810-B74D-AAA7B965200D

Q35051651-61246A84-EF14-4592-92F5-25CC4133052D

Q35051651-7D01E04F-7F38-45DE-8646-486BBDE1D735

Q35051651-8989BD3E-28C6-4BA3-9071-98A64B12A064

P2860

Q35051651-066BE9B6-43C0-4548-B520-8576098E9F88

Q35051651-0B11D203-F1CE-40D9-B80B-13D5230E5893

Q35051651-1360105B-75C9-4AD8-8F4D-826C64C1A5CC

Q35051651-150DEBAC-D1DD-4E1B-A3AB-A0CDE7E0D9F2

Q35051651-1C37792C-5DD0-4FBB-A0BC-88D230BE2B62

Q35051651-2194BAD1-CA54-40C6-B444-29F5AFF14323

Q35051651-2B0A7563-13BD-412F-95F5-37005327C5F3

Q35051651-2C20FF1E-1266-47A7-BBE4-5E7984ACEA2D

Q35051651-30947903-7D31-46F6-BBAD-2C56B97D4C0A

Q35051651-3CED5BFE-FE42-461C-9507-AB0DABED54C2

P304

Q35051651-8E1B329E-2EF2-48FC-991E-0D877BAB3084

P31

Q35051651-6FB0EB38-47DC-4F88-B096-CD399B1AB556

P356

Q35051651-6FBD0079-82A4-49CE-87CA-30001C7C2F67

P433

Q35051651-41AAEF1E-DC54-4BB3-ACB3-FD900D30EBE0

P478

Q35051651-851F0AE8-80DB-4344-8C25-213A2F7204A6

P577

Q35051651-BAED6C18-B214-4671-89B4-AF6015727FD4

P5875

Q35051651-E47DE4E4-D397-4FBE-9FC1-C2015139348D

P698

Q35051651-91E25DE3-B9B6-40D7-B2C0-851D20227B67

P932

Q35051651-C9522B6E-D347-4B7A-9C64-35F0504FF2F3

P356

P1433

P1476

Preclinical antitumor activity ...... ermal growth factor receptor 2

@en

P2093

Eugene P Frenkel

http://www.w3.org/2001/XMLSchema#string

Hidekazu Tanaka

http://www.w3.org/2001/XMLSchema#string

Kanji Hojo

http://www.w3.org/2001/XMLSchema#string

Keiji Dohi

http://www.w3.org/2001/XMLSchema#string

Ken-Ichi Nezasa

http://www.w3.org/2001/XMLSchema#string

Kenji Matsuo

http://www.w3.org/2001/XMLSchema#string

Koichi Masuno

http://www.w3.org/2001/XMLSchema#string

Makiko Inoue

http://www.w3.org/2001/XMLSchema#string

Michinari Hirata

http://www.w3.org/2001/XMLSchema#string

Michitaka Shichijo

http://www.w3.org/2001/XMLSchema#string

P2860

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy.

EGFR-mutated lung cancer: a paradigm of molecular oncology.

The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.

P304

1040-1048

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.12449

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262417309

http://www.w3.org/2001/XMLSchema#string

P698

24837299

http://www.w3.org/2001/XMLSchema#string

P932

4317859

http://www.w3.org/2001/XMLSchema#string